{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000020","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.555822+00:00","generated_at":"2026-06-20T04:00:51.702736+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio cuts US headcount to ~15, consolidates operations to UK, expects cash runway beyond 2026","bullets":["Will extend reduction-in-force to ~15 US employees; transition ITIL-306 manufacturing and trial to Manchester, UK.","Estimates total restructuring costs up to $3.0M, excluding potential facility sale charges.","Evaluating potential sale/sublease of Tarzana, CA manufacturing site to further extend cash runway.","Expects cash runway beyond 2026; initial ITIL-306 clinical data still expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000020","json":"https://secwatch.observer/filing/0001789769-23-000020.json","markdown":"https://secwatch.observer/filing/0001789769-23-000020.md","text":"https://secwatch.observer/filing/0001789769-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/0001789769-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/til-20230130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T04:00:51.702736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}